title: [A murine model of mammary adenocarcinoma (VI TA2MA-891) with high rate of spontaneous metastases in the lungs].
abstract: The primary donor tumor was a spontaneous mammary tumor which arose in a 348-day-old female TA2 mouse. The pedigree number of that mouse was 0901-1423. The mouse was sacrificed for serial s.c. transplantation with 3 isogeneic hosts on January 19, 1989 and a total of 27 generations succeeded by the end of April, 1992. The primary donor tumor was diagnosed pathologically as a type B mouse mammary adenocarcinoma (Dunn 1959). The incidence of this serial s.c. transplantation tumor is 100% after inoculation. The latency period is 4-7 days and the lifetime of tumorbearing mice is about 47 days. The spontaneous metastatic rates in the lungs was 100% after the 11th generations. The earliest metastasis seen in the lung under light microscopy was on the 10th day after inoculation, and the earliest seen by gross examination was on about the 35th day. The transplanted tumor grew slowly from the 4th day to the 21st day after inoculation and then grew rather fast from the 22nd to the 47th day. The average size of the transplanted tumor obtained from 10 recipient mice on the 47th day after inoculation was 4.93cm3. Seven anticancer drugs were administered respectively for a sensitivity test. The taking rates of the transplanted tumor using 4 of the 7 drugs were as follows: 5-fluorouracil 29.27% (P < 0.05); thio-tepa 44.80% (P < 0.01); cyclophosphamide 95.31% (P < 0.01); and bleomycin 96.27% (P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cancer Institute, CAMS and PUMC, Beijing.
authors.forename: P
authors.initials: P
authors.lastname: Gao
authors.forename: Y
authors.initials: Y
authors.lastname: Su
authors.forename: Y
authors.initials: Y
authors.lastname: Gao
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use / Q000031:analogs & derivatives; D004195:Disease Models, Animal; D005260:Female; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D009368:Neoplasm Transplantation
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D001761:Bleomycin; C021771:zhengguangmycin